522 related articles for article (PubMed ID: 30621224)
1. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
2. Immunity against tetanus and diphtheria after childhood sarcoma treatment.
Paulides M; Stöhr W; Laws HJ; Graf N; Lakomek M; Berthold F; Schmitt K; Niggli F; Jürgens H; Bielack S; Koscielniak E; Klingebiel T; Langer T
Klin Padiatr; 2010 May; 222(3):196. PubMed ID: 20514629
[No Abstract] [Full Text] [Related]
3. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Nakamura T; Asanuma K; Hagi T; Sudo A
Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.
Pang A; Carbini M; Maki RG
JAMA Oncol; 2016 Jul; 2(7):941-7. PubMed ID: 27148906
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
7. Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
Tanaka K; Ozaki T
Jpn J Clin Oncol; 2022 May; 52(6):526-530. PubMed ID: 35292817
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
9. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic factors of bone and soft tissue sarcomas].
Furuse K
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2050-5. PubMed ID: 3293534
[TBL] [Abstract][Full Text] [Related]
11. Appraising the current role of chemotherapy for the treatment of sarcoma.
D'Adamo DR
Semin Oncol; 2011 Oct; 38 Suppl 3():S19-29. PubMed ID: 22055968
[TBL] [Abstract][Full Text] [Related]
12. Eribulin in soft-tissue sarcomas.
Maki RG
Lancet Oncol; 2011 Oct; 12(11):988-9. PubMed ID: 21937276
[No Abstract] [Full Text] [Related]
13. Fifty years of advances in sarcoma treatment: moving the needle from conventional chemotherapy to targeted therapy.
Patel SR
Am Soc Clin Oncol Educ Book; 2014; ():259-62. PubMed ID: 24857084
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
16. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
17. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
Mita MM; Gong J; Chawla SP
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
[TBL] [Abstract][Full Text] [Related]
18. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
19. [Pre- and postoperative chemotherapy in bone and soft tissue tumors].
Höffken K
Langenbecks Arch Chir; 1987; 372():311-4. PubMed ID: 3481009
[TBL] [Abstract][Full Text] [Related]
20. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.
Scheinberg T; Lomax A; Tattersall M; Thomas D; McCowage G; Sullivan M; Karim R; Luk PP; Mahar A; Bonar F; Bhadri VA
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1327. PubMed ID: 33314769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
